JP Morgan Chase
ELVN icon

JP Morgan Chase’s Enliven Therapeutics ELVN Stock Holding History

JP Morgan Chase’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
37,890
+17,070
+82% +$725K ﹤0.01% 4153
2026
Q1 		$762K Buy
20,820
+119
+0.6% +$3.3K ﹤0.01% 4760
2025
Q4 		$319K Sell
20,701
-4,117
-17% -$82K ﹤0.01% 5281
2025
Q3 		$508K Buy
24,818
+5,754
+30% +$116K ﹤0.01% 5027
2025
Q2 		$382K Sell
19,064
-2,701
-12% -$51.1K ﹤0.01% 4912
2025
Q1 		$428K Buy
21,765
+2,020
+10% +$43.5K ﹤0.01% 4870
2024
Q4 		$444K Sell
19,745
-1,062
-5% -$27.5K ﹤0.01% 5102
2024
Q3 		$531K Buy
20,807
+13
+0.1% +$301 ﹤0.01% 4860
2024
Q2 		$486K Buy
20,794
+2,407
+13% +$50.7K ﹤0.01% 4708
2024
Q1 		$323K Sell
18,387
-5,602
-23% -$85.9K ﹤0.01% 5069
2023
Q4 		$332K Sell
23,989
-2,506
-9% -$30.7K ﹤0.01% 5040
2023
Q3 		$362K Sell
26,495
-4,160
-14% -$70K ﹤0.01% 4674
2023
Q2 		$626K Buy
30,655
+30,561
+32,512% +$618K ﹤0.01% 4365
2023
Q1 		$2K Buy
+94
New +$1.91K ﹤0.01% 6414
2022
Q4 		– Sell
-2
Closed – – 6651
2022
Q3 		$0 Buy
+2
New +$12 ﹤0.01% 6549
2021
Q4 		– Sell
-2,037
Closed -$33K – 6721
2021
Q3 		$33K Sell
2,037
-486
-19% -$10.1K ﹤0.01% 5936
2021
Q2 		$80K Sell
2,523
-2,730
-52% -$84.7K ﹤0.01% 5612
2021
Q1 		$177K Buy
5,253
+124
+2% +$6.3K ﹤0.01% 5198
2020
Q4 		$453K Buy
5,129
+4,352
+560% +$365K ﹤0.01% 4428
2020
Q3 		$68K Sell
777
-280
-26% -$25.3K ﹤0.01% 4846
2020
Q2 		$117K Buy
+1,057
New +$118K ﹤0.01% 4498

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

JP Morgan Chase's ELVN Position: Q2 2026 in Review

JP Morgan Chase increased its Enliven Therapeutics (ELVN) stake by 82% in Q2 2026, buying an estimated $725K and bringing the position to 37,890 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

JP Morgan Chase first reported a position in ELVN in Q2 2020 and has held it in 21 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • JP Morgan Chase held 37,890 shares of Enliven Therapeutics worth $2.06M as of Q2 2026.
  • JP Morgan Chase bought 17,070 Enliven Therapeutics shares in Q2 2026, an estimated $725K.
  • Enliven Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4153 holding.
  • JP Morgan Chase first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.